Experienced in Embryonal Tumor with Multilayered Rosettes
Experienced in Embryonal Tumor with Multilayered Rosettes
35 Park St, Pediatric Hem Onc Suite 7th Fl, 
New Haven, CT 

Overview

Aron Flagg is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Flagg has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 39 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 12 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

35 Park St, Pediatric Hem Onc Suite 7th Fl, New Haven, CT 06511

Additional Areas of Focus

Dr. Flagg has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


39 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Umbrella Long-Term Follow-Up Protocol
Neuroblastoma Biology Studies
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 34 Less Clinical Trials
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
3415 Bainbridge Ave, 
Bronx, NY 
 (57.2 miles away)
Languages Spoken:
English

Daniel Weiser is a Pediatric Hematologist Oncology provider in Bronx, New York. Dr. Weiser is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Adult Soft Tissue Sarcoma, and Osteosarcoma.

Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Columbia Unversity Department Pediatrics, 3959 Broadway, 
New York, NY 
 (61.5 miles away)
Languages Spoken:
English

Darrell Yamashiro is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Yamashiro is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hereditary Neuroblastoma, and Hepatoblastoma.

Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
20 York St, Ynhh (children's) West Pavilion - 2nd Floor, 
New Haven, CT 
 (0.1 miles away)
Languages Spoken:
English

Nina Kadan is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Kadan is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatoblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flagg's expertise for a condition
ConditionClose
      View All 28 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile